Loading...
•
Mar 31
CryoPort Q1 2025 Earnings Report
Cryoport reported a strong start to the year with increased revenue from continuing operations and improved adjusted EBITDA, driven by growth in Life Sciences Services and stabilization in Life Sciences Products.
Key Takeaways
Cryoport, Inc. announced its first quarter 2025 financial results, reporting total revenue from continuing operations of $41.0 million, a 10% increase year-over-year. The company saw significant growth in its Life Sciences Services segment, up 17% year-over-year, and a stabilization in its Life Sciences Products business. Adjusted EBITDA showed meaningful improvement, reducing the negative figure from $6.7 million in Q1 2024 to $2.8 million in Q1 2025. A strategic partnership with DHL Group, including the divestiture of CRYOPDP, is expected to enhance operational reach and competitive profile.
Total revenue from continuing operations for Q1 2025 was $41.0 million, an increase of 10% year-over-year.
Commercial Cell & Gene therapy revenue increased by 33% year-over-year, contributing to the 17% growth in Life Sciences Services revenue.
Adjusted EBITDA improved significantly, moving from a negative $6.7 million in Q1 2024 to a negative $2.8 million in Q1 2025.
Cryoport supported 711 global clinical trials as of March 31, 2025, a net increase of 36 trials from the previous year.
CryoPort
CryoPort
CryoPort Revenue by Segment
Revenue by Segment
Life Sciences Services Revenue
CapyFin.comBioLogistics Solutions Revenue
CapyFin.comBioStorage/BioServices Revenue
CapyFin.comLife Sciences Products Revenue
CapyFin.com Forward Guidance
Cryoport is reiterating its full-year fiscal 2025 revenue guidance, expecting total organic revenue to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The company anticipates continued growth in Cell & Gene-based therapies and a return to positive adjusted EBITDA during 2025.
Positive Outlook
- Anticipated revenue growth of 5% to 10% year-over-year for fiscal year 2025.
- Expectation of continued increase in development and commercialization of Cell & Gene-based therapies.
- Belief in stabilization of order patterns in Life Sciences Products segment.
- Anticipation of minimal impact from tariffs, with related charges expected to be passed through.
- Strategic partnership with DHL Group expected to enhance operational reach and competitive profile, particularly in APAC and EMEA regions.
Challenges Ahead
- Guidance is dependent on current business and expectations, which may be impacted by factors outside of the company's control.
- Potential impacts from national economic factors and the global macroeconomic and geopolitical environment.
- Risks associated with supply chain constraints and inflationary pressures.
- Potential effects of tariffs and other trade restrictions.
- Risks related to foreign currency fluctuations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income